What it is
Cortagen is a four-residue chain — Ala, Glu, Asp, Pro — made in a laboratory rather than extracted from tissue. Its developers at the St Petersburg Institute of Bioregulation and Gerontology describe it as "obtained by directed synthesis based on amino acid analysis" of Cortexin, a Russian drug made from peptides of animal brain cortex (Anisimov, Khavinson and Anisimov 2004, PMID 15159690). It is one of the short bioregulator peptides of that programme, each named for the organ it is presented for.
| Property | Value | Source |
|---|---|---|
| Sequence | Ala-Glu-Asp-Pro (AEDP) | PMID 15159690; PubChem |
| Length | 4 amino acids | — |
| Formula | C17H26N4O9 | PubChem CID 18439621 |
| Molecular weight | 430.4 | PubChem |
The family resemblance is in the letters. The heart-labelled Cardiogen is Ala-Glu-Asp-Arg, so Cortagen is Cardiogen with proline in place of arginine. The lung-labelled Bronchogen is Ala-Glu-Asp-Leu. The prostate-labelled Prostamax, Lys-Glu-Asp-Pro, shares Cortagen's last three residues.
What PubMed holds
PubMed's title-and-abstract index held 13 cortagen papers, dated 2000 to 2023, when searched on 2026-11-19; not one carries a clinical-trial tag. By subject:
| What was studied | Records (examples) | People given the peptide? |
|---|---|---|
| Nerve regeneration in rats | 2000 Bull Exp Biol Med (PMID 11276314); 2002 Dokl Biol Sci (PMID 12134478) | No |
| Gene activity in mouse heart | 2004 Neuro Endocrinol Lett (PMID 15159690) | No |
| Oxidative damage and brain ischaemia in rats | 2007 (PMID 18239817); 2011 (PMID 21476278) | No |
| Immune signalling in mouse or rat cells | 2002 (PMIDs 12447482, 12420072); 2005 (PMID 16224591); 2006 (PMID 17426849) | No |
| Chromatin in cells from elderly people | 2004 Bull Exp Biol Med (PMID 15085253); 2023 Georgian Med News (PMID 37042594) | No — cells treated in the laboratory |
The most specific result is in rats. After the sciatic nerve was cut and sutured, intramuscular cortagen at 10 µg/kg for 10 days increased the growth rate of regenerating fibres by 27% and their conduction velocity by 40% (Turchaninova et al., PMID 11276314). A 2002 follow-up by the same Pavlov Institute authors reports a delayed effect on recovery (PMID 12134478; abstract not available, title read).
The 2004 gene study injected female mice for five days and measured 15,247 transcripts in the heart: 234 clones, 1.53%, changed, matching 110 known genes, with the largest change a 5.42-fold rise (PMID 15159690). It compared the pattern with those of Vilon, Epitalon and melatonin.
What is not established
- Any effect in people. The 2004 paper's introduction says that "in humans, Cortagen demonstrated a pronounced therapeutic effect" on peripheral nerve recovery, but the abstract gives no study, and no human trial is indexed in PubMed or registered on ClinicalTrials.gov (2026-11-19).
- Independent replication. The records whose affiliations were read come from St Petersburg institutes or their Georgian collaborators, and V. Khavinson is an author on at least eight of the 13.
- Safety. No study reports giving it to a person, so nothing is known about its safety in people.
- That it reaches the brain. None of the records measures whether the peptide crosses into the brain after injection.
Where it stands
Twenty-five years after the sciatic-nerve paper, cortagen's evidence is still rats, mice and dishes of cells, nearly all of it from the laboratories that designed it. Nerve damage, memory complaints and other brain symptoms need a clinician's assessment; this entry sets out the chemistry and the measurements. Related entries: Cortexin, Vilon, Vesugen, Epitalon.
Sources opened 2026-11-19: PubChem (CID 18439621); PubMed E-utilities (search; abstracts of PMIDs 15159690, 11276314, 18239817, 21476278; titles of the other nine); ClinicalTrials.gov API v2.
